Bloomage BioTechnology Corporation Limited

Shanghai Stock Exchange 688363.SS

Bloomage BioTechnology Corporation Limited Net Income Margin for the year ending December 31, 2023: 9.75%

Bloomage BioTechnology Corporation Limited Net Income Margin is 9.75% for the year ending December 31, 2023, a -36.12% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Bloomage BioTechnology Corporation Limited Net Income Margin for the year ending December 31, 2022 was 15.27%, a -3.44% change year over year.
  • Bloomage BioTechnology Corporation Limited Net Income Margin for the year ending December 31, 2021 was 15.81%, a -35.54% change year over year.
  • Bloomage BioTechnology Corporation Limited Net Income Margin for the year ending December 31, 2020 was 24.53%, a -21.01% change year over year.
  • Bloomage BioTechnology Corporation Limited Net Income Margin for the year ending December 31, 2019 was 31.06%, a -7.45% change year over year.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
Loading...
Shanghai Stock Exchange: 688363.SS

Bloomage BioTechnology Corporation Limited

CEO Ms. Yan Zhao
IPO Date Nov. 12, 2019
Location China
Headquarters Tech Development Zone
Employees 4,655
Sector Health Care
Industries
Description

Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names. Bloomage BioTechnology Corporation Limited was founded in 2000 and is headquartered in Jinan, the People's Republic of China.

Similar companies

300015.SZ

Aier Eye Hospital Group Co., Ltd.

USD 1.73

3.02%

002821.SZ

Asymchem Laboratories (Tianjin) Co., Ltd.

USD 10.09

5.71%

600763.SS

Topchoice Medical Corporation

USD 5.73

2.34%

300896.SZ

Imeik Technology Development Co.,Ltd.

USD 23.99

3.90%

688012.SS

Advanced Micro-Fabrication Equipment Inc. China

USD 25.70

5.31%

StockViz Staff

January 15, 2025

Any question? Send us an email